Zhengye Biotechnology (ZYBT) - Gunggung dhuwit awis saben saham

Zhengye Biotechnology - logo grafis emiten ZYBT

A steady capital inflow from the sale of veterinary products supports current R&D expenditures for Zhengye Biotechnology (ZYBT). An analysis of the issuer's cash per share confirms financial resilience, where the 0.10 mark indicates the level of the assets' defensive barrier. Such stability is based on leadership within the Chinese biologicals sector and the flawless trust of farmers in the quality of Zhengye Biotechnology vaccines.

Zhengye Biotechnology - Dana dhuwit saben saham ZYBT (periode 08.01.2025 - 20.11.2026)

Rincian analitis perusahaan Zhengye Biotechnology

- nilai saham lan prakiraan konsensus rega:
- indikator anane dhuwit lan arus kas:
Ringkesan analisis perusahaan:ZYBT - Zhengye Biotechnology
Produk merek Zhengye Bio

This metric reflects net liquidity per ordinary share, allowing for an assessment of the company's real cash reserves net of liabilities. For Zhengye Biotechnology (ZYBT), amid expansion into the growing Asian veterinary drug market, monitoring cash per share helps distinguish strategic reserves for business scaling from inefficient capital accumulation, eliminating distortions caused by infrequent quarterly reporting.